Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. 2014

Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, Tokyo, Japan. Department of Applied Chemistry, National Defense Academy, Yokosuka, Kanagawa, Japan.

Involvement of Ras in cancer initiation is known, but recent evidence indicates a role in cancer progression, including metastasis and invasion; however, the mechanism is still unknown. In this study, it was determined that human lung cancer cells with Ras mutations, among other popular mutations, showed significantly higher expression of CUB domain-containing protein 1 (CDCP1) than those without. Furthermore, activated Ras clearly induced CDCP1, whereas CDCP1 knockdown or inhibition of CDCP1 phosphorylation by Src-directed therapy abrogated anoikis resistance, migration, and invasion induced by activated-Ras. Activation of MMP2 and secretion of MMP9, in a model of Ras-induced invasion, was found to be regulated through induction of phosphorylated CDCP1. Thus, CDCP1 is required for the functional link between Ras and Src signaling during the multistage development of human malignant tumors, highlighting CDCP1 as a potent target for treatment in the broad spectrum of human cancers associated with these oncogenes. CONCLUSIONS CDCP1 protein induced by oncogenic Ras/Erk signaling is essential for Ras-mediated metastatic potential of cancer cells.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011905 Genes, ras Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein. Ha-ras Genes,Ki-ras Genes,N-ras Genes,c-Ha-ras Genes,c-Ki-ras Genes,c-N-ras Genes,ras Genes,v-Ha-ras Genes,v-Ki-ras Genes,H-ras Genes,H-ras Oncogenes,Ha-ras Oncogenes,K-ras Genes,K-ras Oncogenes,Ki-ras Oncogenes,N-ras Oncogenes,c-H-ras Genes,c-H-ras Proto-Oncogenes,c-Ha-ras Proto-Oncogenes,c-K-ras Genes,c-K-ras Proto-Oncogenes,c-Ki-ras Proto-Oncogenes,c-N-ras Proto-Oncogenes,ras Oncogene,v-H-ras Genes,v-H-ras Oncogenes,v-Ha-ras Oncogenes,v-K-ras Genes,v-K-ras Oncogenes,v-Ki-ras Oncogenes,Gene, Ha-ras,Gene, Ki-ras,Gene, v-Ha-ras,Gene, v-Ki-ras,Genes, Ha-ras,Genes, Ki-ras,Genes, N-ras,Genes, v-Ha-ras,Genes, v-Ki-ras,H ras Genes,H ras Oncogenes,H-ras Gene,H-ras Oncogene,Ha ras Genes,Ha ras Oncogenes,Ha-ras Gene,Ha-ras Oncogene,K ras Genes,K ras Oncogenes,K-ras Gene,K-ras Oncogene,Ki ras Genes,Ki ras Oncogenes,Ki-ras Gene,Ki-ras Oncogene,N ras Genes,N ras Oncogenes,N-ras Gene,N-ras Oncogene,c H ras Genes,c H ras Proto Oncogenes,c Ha ras Genes,c Ha ras Proto Oncogenes,c K ras Genes,c K ras Proto Oncogenes,c Ki ras Genes,c Ki ras Proto Oncogenes,c N ras Genes,c N ras Proto Oncogenes,c-H-ras Gene,c-H-ras Proto-Oncogene,c-Ha-ras Gene,c-Ha-ras Proto-Oncogene,c-K-ras Gene,c-K-ras Proto-Oncogene,c-Ki-ras Gene,c-Ki-ras Proto-Oncogene,c-N-ras Gene,c-N-ras Proto-Oncogene,ras Gene,ras Oncogenes,v H ras Genes,v H ras Oncogenes,v Ha ras Genes,v Ha ras Oncogenes,v K ras Genes,v K ras Oncogenes,v Ki ras Genes,v Ki ras Oncogenes,v-H-ras Gene,v-H-ras Oncogene,v-Ha-ras Gene,v-Ha-ras Oncogene,v-K-ras Gene,v-K-ras Oncogene,v-Ki-ras Gene,v-Ki-ras Oncogene
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell

Related Publications

Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
April 2004, Seminars in cancer biology,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
January 2011, Proceedings of the National Academy of Sciences of the United States of America,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
June 2017, Cell reports,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
September 2022, International journal of molecular sciences,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
January 2012, Methods in molecular biology (Clifton, N.J.),
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
September 2017, Cancer research,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
January 2021, Frontiers in cell and developmental biology,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
April 2017, Science signaling,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
July 2022, Nature communications,
Takamasa Uekita, and Satoko Fujii, and Yuri Miyazawa, and Reika Iwakawa, and Mako Narisawa-Saito, and Katsuhiko Nakashima, and Koji Tsuta, and Hitoshi Tsuda, and Tohru Kiyono, and Jun Yokota, and Ryuichi Sakai
September 2016, Cancer research,
Copied contents to your clipboard!